IL-17 and IL-23 blockers and psilocybin.
10 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Also searched as IL-17 blocker · IL-17 blockers · IL-17 inhibitor · IL-23 blocker · IL-23 blockers · IL-23 inhibitor · interleukin blocker · interleukin inhibitor
01 What the evidence covers
Best evidence available per medication| 10 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZPlaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, its label warns of infections and of suicidal thoughts and behavior.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Moderate-to-severe plaque psoriasis (adults, after other systemic therapies)
Not studied with psilocybin; no linking mechanism is described. Also, its boxed warning covers suicidal thoughts and behavior.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Plaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Moderate-to-severe plaque psoriasis (adults and children 12 years and older, at least 40 kg)
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Plaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Ulcerative colitis; Crohn's disease
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Plaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Moderate-to-severe plaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Moderate-to-severe plaque psoriasis; Psoriatic arthritis
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Ustekinumab · Stelara, Wezlana, Selarsdi, Pyzchiva, Otulfi, Imuldosa, Yesintek, Steqeyma, StarjemzaEvidence: No psilocybin data
Plaque psoriasis (adults and children 6 years and older); Psoriatic arthritis (adults and children 6 years and older)
Not studied with psilocybin; no linking mechanism is described. Also, it acts on the immune system.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 2 | Psychiatric reactions |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRecords reviewed 2026-11-02 to 2026-11-09. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z